Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABM 1310

Next Previous
Drug Profile

ABM 1310

Alternative Names: ABM-1310

Latest Information Update: 18 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ABM Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein b-raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Brain cancer; Solid tumours
  • Preclinical Colorectal cancer

Most Recent Events

  • 03 Mar 2025 Updated efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the European Society for Medical Oncology Targeted Anticancer Therapies Congress (ESMO TAT-2025)
  • 13 Sep 2024 Interim adverse events, pharmacokinetics, and efficacy data from a phase-I trial in Brain cancer presented at the 49th European Society for Medical Oncology Congress) (ESMO-2024),
  • 27 Aug 2024 ABM Therapeutics Shanghai Company Limited terminates a phase I trial in Brain cancer (Second-line therapy or greater, Metastatic disease) in China due to the adjustment of the applicant's research and development strategy (PO) (NCT05892653)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top